Abstract: Antibodies and antigen-binding fragments thereof that bind the human voltage-gated sodium channel Nav1.7? protein subunit (Nav1.7 binders) are described. In particular embodiments, the Nav1.7 binders comprise a heavy-chain immunoglobulin single variable domain (ISVD or VHH).

Abstract: This disclosure provides methods of making immune effector cells (for example, T cells, NK cells) that comprise (i) a nucleic acid molecule that encodes a controllable chimeric antigen receptor (CCAR) or (ii) a nucleic acid molecule that encodes a CAR and a regulatory molecule, and compositions generated by such methods.

Abstract: The embodiments herein disclose a method and system for process automation in computing by implementing a Robotic Process Automation software arm component used for automation of tasks that involves transactional activities like reading from a document, application, writing into a system or application and so on. The process automation allows workflow generation for automation of business user activities on numerous operating systems and works with multiple platforms, environments and applications. Further, a process automation system also supports handling of runtime environment exceptions and audit log. A separate interface is not required by user for (easy) maintenance, as the interface supports admin configuration and run mode access. Internal/embedded documentation of process and unit level control on automation is supported while also supporting automating keyboard activities, mouse operations, wait/smart wait time feature, visual interaction and so on.

Abstract: The embodiments herein disclose a method and system for process automation in computing by implementing a Robotic Process Automation software arm component used for automation of tasks that involves transactional activities like reading from a document, application, writing into a system or application and so on. The process automation allows workflow generation for automation of business user activities on numerous operating systems and works with multiple platforms, environments and applications. Further, a process automation system also supports handling of runtime environment exceptions and audit log. A separate interface is not required by user for (easy) maintenance, as the interface supports admin configuration and run mode access. Internal/embedded documentation of process and unit level control on automation is supported while also supporting automating keyboard activities, mouse operations, wait/smart wait time feature, visual interaction and so on.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Crystallization of the 70 kDa ribosomal protein S6 kinase polypeptide 1 (p70S6K1) kinase domain for X-ray crystallography analysis to generate the three-dimensional structure of the p70S6K1 kinase domain is described. Further described is the use of the three 5 dimensional structure of p70S6K1 kinase domain for identifying and designing ligands or low molecular weight molecules that specifically bind to and modulate (inhibit) the kinase activity of p70S6K1. These ligands or molecules can be used for the treatment of metabolic disorders such as diabetes and for the treatment of various cancers.

Abstract: The invention provides methods and compositions for use in identifying inhibitors of biochemical pathways important for persistent infection, allowing the identification and/or design of improved therapeutics for treating persistent infections by pathogenic microbes. Particularly disclosed is the importance of the glyoxylate shunt to the persistent phase of various infectious agents, including Mycobacteria, such as M. tuberculosis, and the identification of preferred targets for drug development, including the enzymes isocitrate lyase (ICL) and malate synthase. Crystals and three-dimensional structures of M. tuberculosis ICL, without ligand and in complex with two inhibitors are also disclosed, for exemplary use in the design of inhibitors and therapeutic agents.